Researchers at the University of Alabama at Birmingham will study individuals with genetic mutations associated with Parkinson’s disease as one of 32 clinical sites of the Parkinson’s Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
PPMI will enroll participants with a known mutation of the LRRK or SNCA [alpha-synuclein] gene. Previous research has shown these mutations are associated with Parkinson’s disease and account for a greater number of PD cases among certain ethnic populations and families, notably the LRRK2 mutation in those of Ashkenazi (Eastern European) Jewish, Basque and North African Berber descent. The insight investigators glean from these research volunteers will fortify current efforts to develop a disease-modifying therapy, something that currently eludes the field.
“Studying individuals with genetic mutations associated with Parkinson’s can accelerate our research toward a PD biomarker and more effective treatments,” said David Standaert, M.D., Ph.D., chair of the Department of Neurology and primary investigator at UAB. “Although known genetic mutations account for only five to 10 percent of all Parkinson’s cases, this population can provide invaluable information about the intricacies of the disease for all patients.”
PPMI is studying clinical and imaging data and biological samples of people with a genetic mutation to identify biomarkers and speed clinical trials. PPMI will enroll 250 people with the LRRK2 mutation and Parkinson’s, and 250 people with the mutation but without Parkinson’s. Since the SNCA mutation is more rare, the study is recruiting 50 people with Parkinson’s and the mutation, and 50 people with the SNCA mutation but without PD. These participants will be followed for five years.
Interested individuals can visit www.michaeljfox.org/ppmi/genetics, call 877-836-8108 or e-mail email@example.com. PPMI is particularly interested in testing individuals of Ashkenazi (Eastern European) Jewish descent or their relatives with Parkinson’s. The LRRK2 mutation also accounts for more PD cases in people of North African Arab Berber or Basque descent. Study sites will recruit people with the rarer SNCA mutation through familial connections.
Biomarkers — such as cholesterol level for heart disease — are substances, processes or characteristics of the body that communicate disease risk, onset and/or progression. They aid in diagnosis and disease management and help researchers stratify for clinical trials and test new drugs more quickly by measuring biological changes rather than waiting for clinical improvement. There are no validated biomarkers for Parkinson’s disease, a reality researchers are hoping to change with PPMI.
Launched in 2010, PPMI is a longitudinal clinical study that collects standardized clinical, imaging and biologic data. Now taking place at 32 clinical sites around the world, the study completed initial enrollment of 423 recently diagnosed Parkinson’s patients and 196 controls in April 2013. That month, PPMI began recruiting individuals with the known Parkinson’s risk factors of smell loss and REM sleep behavior disorder.
“In the fourth year of PPMI, it is evident that a large-scale biomarker study is not only possible in Parkinson’s disease, but is already yielding scientific insights that could help transform the field of Parkinson’s research,” said Todd Sherer, Ph.D., CEO of The Michael J. Fox Foundation. “The exceptional investigators at sites around the world, such as at UAB, have created the infrastructure that allows us to make such strides, by working together.”
UAB study finds possible frontline therapy for older patients with Hodgkin LymphomaUAB researcher reports that brentuximab vedotin may be effective therapy for older patients with Hodgkin Lymphoma who cannot tolerate standard therapy.posted 2 days ago 380 viewsUAB Medicine-Leeds clinic to open Oct. 21The new internal medicine and pediatric clinic will feature an outpatient diagnostic center with a cutting-edge imaging facility and full ambulatory lab services, all on-site.posted 9 days ago 1913 viewsFirst season of free, weekly Thursday Arts Experiences at UAB Hospital kicks off Oct. 1The UAB Hospital Auxiliary, in partnership with the UAB Institute for Arts in Medicine, presents the series, which will take place in UAB Hospital’s North Pavilion.posted 9 days ago 1819 viewsUAB to lead $9.4 million trial to improve blood pressure in the Black BeltUAB is leading a team of researchers in a trial to combat blood pressure risk factors.posted 9 days ago 2068 viewsUAB to host critical care symposium Oct. 1Register today for UAB’s annual Critical Care Symposium.posted 12 days ago 1191 viewsUAB Medicine Urgent Care announces facility expansionUAB Medicine Urgent Care has announced an expansion to its facility located at 125 20th St. South, Suite 103.posted 13 days ago 1285 viewsNewsweek Top Cancer Doctors 2015 includes UAB cancer specialistsMany UAB physicians from a variety of specialties appear on the prestigious Newsweek Top Cancer Doctors 2015 list.posted 13 days ago 3340 viewsAnswers to age-old questions: Austad explores the science of agingTo learn the secrets of healthy aging, Steven Austad consults the experts: 500-year-old clams, 200-year-old fish, and other ancient animals. His studies reveal aging’s molecular mechanisms, which could help humans live longer and healthier. Get his advice on healthy aging, and discover how a new UAB research center will launch an age of discovery.posted 14 days ago 1287 viewsNovel research shows social factors may impact younger leukemia patients’ survivalNew UAB research demonstrates social factors that determine survival of younger patients with AML and present opportunities to improve outcomes.posted 23 days ago 3015 viewsLandmark study shows intensive blood pressure management may save livesLower blood pressure target of 120 mm Hg greatly reduces cardiovascular complications and deaths in older adults.posted 26 days ago 2697 viewsLatest in prostate cancer detection — now offered at UAB — results in fewer unnecessary biopsiesThe prostate-specific antigen, or PSA, test has limitations, but the new Prostate Health Index can offer an exact percentage of prostate cancer risk.posted 29 days ago 1681 viewsTips on insomnia, snooze buttons, hot baths, putting phones away and moreTips from a UAB sleep physician on ways to help fall asleep and wake up refreshed.posted a while back 1762 viewsNIH awards nearly $34 million to UAB Center for Clinical and Translational ScienceThis renewing of UAB’s prestigious Center for Translational Science Award will bolster research and workforce development at UAB and throughout its regional partner network in the Southeast.posted a while back 7357 viewsCommunity of the South: Donors help stretch UAB Kidney Chain to record 51 transplantsFifty-first transplant means 102 total surgeries have been performed since December 2013 as the nation’s longest-ever chain continues to grow.posted a while back 10556 viewsUAB’s ROSA robot guides new epilepsy procedureA new surgical robot helps UAB physicians add a new technique for preparing for epilepsy surgery.posted a while back 3285 views
In cancer's aftermath, helping survivors confront "late effects"Smita Bhatia, M.D., M.P.H., director of UAB's new Institute for Cancer Outcomes and Survivorship, explains how cancer treatments can lead to chronic health conditions in later life — and how "survivorship clinics" will help.posted a while back 2196 viewsOn the front lines of the heroin epidemic, offering a lifesaving treatmentNaloxone kits have prevented more than 10,000 deaths from opioid overdose since local distribution programs began in 1996. Now, as deaths from opioid overdose reach an all-time high in the United States, a crowdfunded project from UAB researchers aims to put naloxone in the hands of those at highest risk.posted a while back 1396 viewsCreative approaches to healing at UAB’s Institute for Arts in Medicine inspire patients and clinicians
About half of American hospitals have some form of arts programming, usually art or music therapy. Now a growing number of medical centers — UAB Hospital is the first in Alabama — are implementing the more comprehensive AIM model.UAB re-verified as a Level I Trauma Center through 2018The American College of Surgeons has again verified UAB as a Level I Trauma Center, a designation held by UAB since 1999.posted a while back 4967 viewsA lifetime of insights gained from a few hours without sight
UAB ophthalmologists have dinner in the dark to gain better understanding of what it means to be vision-impaired.